◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › O › OCUL

Ocular Therapeutix Inc (OCUL) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-06

Ocular Therapeutix Inc (OCUL) operates in the BIOTECHNOLOGY industry and is headquartered in Bedford, United States with about 325 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, OCUL reported $52M in revenue and ($266M) in net income.

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.

Interactive charts & full statements → Open the OCUL valuation workbench →

OCUL Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Total Revenue	$52M	$52M	$64M	$58M	$51M	$44M	$17M	$4M	$2M	$2M	$2M	$2M	$1M	—	$0M
Gross Profit	$45M	$45M	$58M	$53M	$47M	$39M	$15M	$2M	$2M	$1M	$1M	$1M	$1M	($11M)	$0M
Gross Margin %	87.1%	87.3%	91.2%	91.0%	91.2%	89.9%	88.0%	45.0%	76.6%	76.2%	76.5%	81.8%	88.2%	—	30.0%
Operating Income (EBIT)	($314M)	($270M)	($172M)	($82M)	($79M)	($78M)	($63M)	($86M)	($59M)	($62M)	($43M)	($38M)	($27M)	($13M)	($14M)
Operating Margin %	-603.0%	-521.0%	-269.6%	-141.0%	-152.7%	-179.3%	-361.1%	-2029.9%	-2970.8%	-3220.1%	-2296.0%	-2182.7%	-3509.6%	—	-136710.0%
Net Income	($301M)	($266M)	($194M)	($81M)	($71M)	($7M)	($156M)	($86M)	($58M)	($63M)	($45M)	($40M)	($29M)	($13M)	($14M)
Net Margin %	-579.1%	-513.2%	-303.7%	-138.1%	-137.9%	-15.1%	-894.3%	-2043.3%	-2899.1%	-3296.2%	-2369.0%	-2271.3%	-3710.9%	—	-140930.0%
EBITDA	($285M)	($250M)	($176M)	($66M)	($62M)	$3M	($146M)	($78M)	($56M)	($60M)	($42M)	($37M)	($27M)	($12M)	($13M)
Earnings Per Share (EPS)	$-1.41	$-1.42	$-1.22	$-0.94	$-0.86	$-0.08	$-2.56	$-1.91	$-1.51	$-2.20	$-1.80	$-1.71	$-2.69	$-4.51	$-4.77
Shares Outstanding (M)	225M	187M	158M	86M	83M	82M	61M	45M	38M	29M	25M	23M	11M	3M	3M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

OCUL Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$13M	$11M	$13M	$15M	$13M	$11M	$17M	$15M
Gross Profit	$11M	$9M	$12M	$13M	$12M	$9M	$16M	$14M
Gross Margin %	85.1%	87.7%	88.0%	87.8%	85.6%	88.2%	92.8%	89.9%
Operating Income (EBIT)	($82M)	($93M)	($70M)	($69M)	($68M)	($64M)	($51M)	($46M)
Operating Margin %	-609.3%	-865.5%	-526.5%	-472.3%	-502.6%	-597.5%	-296.1%	-298.2%
Net Income	($79M)	($89M)	($65M)	($69M)	($68M)	($64M)	($48M)	($36M)
Net Margin %	-584.5%	-821.6%	-488.0%	-477.3%	-503.9%	-598.7%	-283.3%	-236.6%
EBITDA	($74M)	($85M)	($61M)	($65M)	($64M)	($60M)	($44M)	($32M)
Earnings Per Share (EPS)	$-0.35	$-0.40	$-0.29	$-0.38	$-0.39	$-0.38	$-0.29	$-0.22
Shares Outstanding (M)	225M	224M	223M	184M	173M	169M	168M	167M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

OCUL Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Cash from Operations (CFO)	($238M)	($205M)	($135M)	($70M)	($60M)	($66M)	($54M)	($78M)	($49M)	($50M)	($34M)	($34M)	($20M)	($13M)	($13M)
Capital Expenditures (CapEx)	$17M	$12M	$1M	$6M	$4M	$1M	$1M	$2M	$2M	$8M	$2M	$2M	$1M	$0M	$0M
Free Cash Flow (FCF)	($255M)	($217M)	($136M)	($76M)	($63M)	($67M)	($54M)	($80M)	($51M)	($59M)	($36M)	($36M)	($22M)	($13M)	($13M)
FCF Margin %	-490.1%	-418.5%	-213.4%	-130.6%	-123.0%	-153.4%	-312.6%	-1888.2%	-2568.6%	-3053.8%	-1903.5%	-2029.8%	-2818.1%	—	-127880.0%
Dividends Paid	—	—	—	$53M	—	$1M	$1M	$37M	$0M	$4M	$0M	$2M	$15M	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

OCUL Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($67M)	($66M)	($54M)	($51M)	($55M)	($45M)	($39M)	($37M)
Capital Expenditures (CapEx)	$3M	$5M	$3M	$6M	$1M	$2M	$0M	$0M
Free Cash Flow (FCF)	($71M)	($71M)	($57M)	($57M)	($56M)	($47M)	($40M)	($37M)
FCF Margin %	-524.2%	-655.1%	-430.9%	-390.0%	-419.7%	-435.6%	-232.0%	-237.6%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

OCUL Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Total Assets	$671M	$808M	$458M	$252M	$149M	$205M	$262M	$79M	$73M	$55M	$75M	$110M	$78M	$19M	$25M
Cash & Cash Equivalents	$599M	$737M	$392M	$196M	$102M	$164M	$228M	$54M	$54M	$42M	$33M	$31M	$37M	$18M	$24M
Total Liabilities	$151M	$154M	$143M	$161M	$114M	$117M	$186M	$82M	$37M	$29M	$23M	$21M	$19M	$79M	$72M
Total Debt (Short + Long-Term)	$76M	$74M	$70M	$77M	$56M	$53M	$51M	$50M	$25M	$18M	$16M	$31M	$15M	$2M	$4M
Total Shareholders' Equity	$520M	$654M	$315M	$91M	$35M	$88M	$76M	($4M)	$36M	$26M	$52M	$90M	$59M	($59M)	($47M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive OCUL viewer.

Other Companies in BIOTECHNOLOGY

SLS · Sellas Life Sciences Group Inc — $2 billion
NKTR · Nektar Therapeutics — $2 billion
AUPH · Aurinia Pharmaceuticals Inc — $2 billion
GENB · Generate Biomedicines, Inc. Common Stock — $2 billion
PVLA · Palvella Therapeutics, Inc — $2 billion
TRVI · Trevi Therapeutics Inc — $2 billion
SRPT · Sarepta Therapeutics Inc — $2 billion
URGN · UroGen Pharma Ltd — $2 billion

← OCTZ All “O” companies ODBA →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.